Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720530 | 1.00 | CTSK (0.50) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL8320677 | 1.00 | CTSK (0.50) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL117269 | 0.91 | BTK (0.51) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL21597571 | 0.90 | BTK (0.55) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL10239204 | 0.90 | BTK (0.55) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL132145 | 0.90 | BTK (0.55) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL24874466 | 0.89 | BTK (0.54) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL13735251 | 0.89 | BTK (0.54) | CTSKBTKGAANFKB1NFKB2 | |
| Bicarbonate SCHEMBL3395208 | 0.88 | BTK (0.53) | CTSKBTKGAANFKB1NFKB2 | |
| SCHEMBL570801 | 0.85 | GAA (0.54) | CTSKBTKGAANFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600698-B2 | Kinase inhibitors | VIDYA THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260042781-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4680607-A1 | BICYCLIC UREAS AS KINASE INHIBITORS | Incyte Corporation (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12503445-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2025-12-23 | — | — | US | disclosed |
| EP-4628490-A2 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2025-10-08 | — | — | EP | disclosed |
| US-20250304582-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORPORATION | 2025-10-02 | — | — | US | disclosed |
| EP-4363406-B1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250090524-A1 | BTK INHIBITORS | BIOGEN MA INC. | 2025-03-20 | — | — | US | disclosed |
| US-20240383862-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-11-21 | — | — | US | disclosed |
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011156610-A2 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| US-20110263575-A1 | Compounds Useful as Protein Kinase Inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2011-10-27 | — | — | US | disclosed |
| US-20110263575-A1 | Compounds Useful as Protein Kinase Inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2011-10-27 | — | — | US | disclosed |
| US-20110263575-A1 | Compounds Useful as Protein Kinase Inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2011-10-27 | — | — | US | disclosed |
| CN-101952291-A | 4-(9-(3, 3-difluorocyclopentyl)-5,7, 7-trimethyl-6-oxo-6, 7,8, 9-tetrahydro-5H-pyrimidino [4,5-B] [1,4] diaza-2-ylamino)-3-methoxybenzamide derivatives useful as inhibitors of human protein kinases PLK1 to PLK4 for the treatment of proliferative diseases | VERTEX PHARMA | 2011-01-19 | — | — | CN | disclosed |
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
| EP-2190849-A2 | COMPOUNDS USEFUL AS PROTEIN KINASES INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009023269-A2 | 4-(9-(3, 3-DIFLUOROCYCLOPENTYL) -5, 7, 7-TRIMETHYL-6-OXO-6, 7, 8, 9-TETRAHYDRO-5H-PYRIMIDO [4, 5-B[1, 4] DIAZEPIN-2-YLAMINO)-3-METHOXYBENZAMIDE DERIVATIVES AS INHIBITORS OF THE HUMAN PROTEIN KINASES PLK1 TO PLK4 FOR THE TREATMENT OF PROLIFERATIVE DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
| US-7365205-B2 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, FABP1, EIF2AK2 | CTSK 376/4885BTK 2673/4885GAA 456/4885 |
| US-20250304582-A1 | Bicyclic Ureas As Kinase Inhibitors | JAK2, UCK2, ULK2 | CTSK 1912/4885BTK 63/4885GAA 3961/4885 |
| US-12600698-B2 | Kinase inhibitors | BTK, BMX, GSK3B | CTSK 3060/4885BTK 1/4885GAA 1323/4885 |
| US-20240383862-A1 | COMPOUNDS AND THEIR USE | NLRP3, PYCARD, NLRP1 | CTSK 947/4885BTK 1222/4885GAA 2173/4885 |
| US-20250090524-A1 | BTK INHIBITORS | BTK, SYK, LYN | CTSK 1350/4885BTK 1/4885GAA 1344/4885 |
| US-20260042781-A1 | Bicyclic Ureas As Kinase Inhibitors | NR0B1, NR2C2, ERBB2 | CTSK 4005/4885BTK 156/4885GAA 4825/4885 |
| US-20110263575-A1 | Compounds Useful as Protein Kinase Inhibitors | MAP3K20, PRKCH, PACSIN2 | CTSK 782/4885BTK 251/4885GAA 649/4885 |
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC2, PGRMC1 | CTSK 4301/4885BTK 2652/4885GAA 4768/4885 |
| US-12503445-B2 | Compounds and their use | NLRP3, PYCARD, NLRP1 | CTSK 947/4885BTK 1222/4885GAA 2173/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | CTSK 3692/4885BTK 2261/4885GAA 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.